[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dengue-fever\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dengue-fever":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,69,93,123,151,182,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100567196","phase-3-a-study-of-2-doses-of-tetravalent-dengue-vaccine-tdv-in-infants-and-toddlers-100567196",false,"NCT06665035","A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers","A Randomized, Age-Descending, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Safety and Immunogenicity of 2 Doses of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Within the Routine Vaccination Schedule of Pediatric Participants ≥6 Months to \u003C21 Months of Age","Inclusion Criteria\n\nParticipant eligibility is determined according to the following criteria:\n\n1. Participant is aged \\>=6 to \\\u003C21 months at the time of entry into the trial.\n2. Participant is male or female.\n3. Participant is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator.\n4. Participant's legally acceptable representative (LAR) has signed and dated a written informed consent form (ICF) and any required privacy authorization prior to the initiation of any trial procedure, and after the nature of the trial has been explained according to local regulatory requirements.\n5. The participant and participant's LAR can comply with trial procedures and can be available for the duration of follow-up, according to the LAR.\n\nExclusion Criteria\n\nAny participant who meets any of the following criteria will not qualify for randomization:\n\n1. Participant has contraindication(s), warning(s) and\u002For precaution(s) applicable to vaccination with TDV as specified in the investigator's brochure (IB)and\u002For the approved product label (as applicable) in the participating country.\n2. Participant has a known hypersensitivity or allergy to any of the investigational medicinal product (IMP) components (including excipients).\n3. Participant has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.\n4. Participant has a history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (example, Guillain-Barré syndrome).\n5. Participant has an illness, or history of any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participant due to involvement in this trial.\n6. Participant has a known or suspected impairment\u002Falteration of immune function, including:\n\n   1. Chronic administration of oral and\u002For parenteral steroids at doses considered sufficiently immunosuppressive (example, \\>=2 mg\u002Fkg \\[milligrams per kilograms\\] body weight\u002Fday prednisone \\[or equivalent\\] for 14 consecutive days, or, \\>=20 milligram per day \\[mg\u002Fday\\] prednisone \\[or equivalent\\] for \\>=14 consecutive days) within 60 days prior to Day 1 month 0 (M0) (note: use of corticosteroids by inhaled, intranasal, intraarticular, bursal, tendon injection, or topical routes is allowed).\n   2. Receipt of blood, immunoglobulins, blood products, and\u002For plasma derivatives within the 3 months prior to Day 1 (M0).\n   3. Receipt of immunostimulants within 60 days prior to Day 1 (M0).\n   4. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).\n   5. HIV infection or HIV-related disease.\n   6. Hepatitis B virus infection.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n7. Participant has known or suspected abnormalities of splenic or thymic function.\n8. Participant has a known bleeding diathesis, or any condition\u002Fmedication that may be associated with a prolonged bleeding time.\n9. Participant has a serious chronic or progressive disease deemed to be preclusive to trial entry, that is., not medically stable according to the judgment of the investigator.\n10. Participant has previously received a vaccination against dengue virus (investigational or licensed).\n11. Participant has a clinically significant active infection (as assessed by the investigator) or body temperature greater than (\\>) 38.0 degrees Celsius (°C) (\\>100.4 degrees Fahrenheit \\[°F\\]) within 3 days of intended IMP administration on Day 1 (M0).\n12. Participant has used antipyretics and\u002For analgesic medications within 24 hours prior to vaccination. The reason for their use (prophylaxis vs treatment) must be documented. Trial entry must be delayed to allow for a full 24 hours to have passed since last use of antipyretics and\u002For analgesic medications.\n13. Participant has received any of the following:\n\n    1. A licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to IMP administration on Day 1 (M0). This includes co-administration with routine vaccines.\n    2. A coronavirus vaccine within 14 days prior to IMP administration on Day 1 (M0).\n    3. A vaccine authorized for emergency use within 28 days prior to IMP administration on Day 1 (M0).\n14. Participant is scheduled to receive any other vaccine within 28 days after IMP administration on Day 1 (M0).\n15. Participant is participating in any clinical trial with another investigational product 30 days prior to Day 1 (M0) or plans to participate in another clinical trial at any time during the conduct of this trial.\n16. Participant has taken part in any clinical trial of a dengue or other flavivirus (example, West Nile virus) candidate vaccine, except if it is known that the participant received placebo in the trial(s).\n17. A first degree relative is involved in the conduct of this trial.",true,"ALL","6 Months","20 Months",{"count":21,"type":22},212,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The purpose of this study is to collect information of vaccination with TDV when given to children younger than 2 years. The main aims of this study are to learn how safe the vaccine is and how well it works to activate a young child's immune system (this is called immunogenicity). Children between the age of 6 and 21 months will receive two vaccinations with either TDV or placebo 3 months apart. Blood samples will be taken before and after the vaccination as well as throughout the study. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 8 times for vaccinations, blood draws and health checks.",[28],"Dengue Fever",[30],"Drug Therapy","RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2025-06-16",{"date":39,"type":22},"2030-03-03",{"name":41,"class":42},"Takeda","INDUSTRY",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100560638","phase-3-a-study-of-dengue-tetravalent-vaccine-tdv-in-adults-age-45-to-60-and-60-to-79-years-100560638","NCT06579755","A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue","Inclusion Criteria:\n\n1. Participant is aged 45 to 79 years at the time of entry into the trial.\n2. Participant is male or female.\n3. Participant is in good health or has a medical diagnosis of one or more of diabetes mellitus, hypertension, or chronic kidney disease (that is, comorbidities) and are medically stable in the opinion of the investigator at the time of entry into the trial, as determined by medical history and targeted physical examination. Medically stable is defined as no change in diagnoses or chronic medications (dose or class) for medical reasons in the 3 months prior to participating in the trial.\n4. Participant has signed and dated a written informed consent form and any required privacy authorization prior to the initiation of any trial procedure, and after the nature of the trial has been explained according to local regulatory requirements.\n5. Participant can comply with trial procedures and is available for the duration of follow-up.\n\nExclusion Criteria:\n\n1. Participant has contraindication(s), warning(s), and\u002For precaution(s) applicable to vaccination with TDV as specified in the Investigator's Brochure and\u002For approved product label (as applicable) in the participating country.\n2. Participant has a known hypersensitivity or allergy to any of the TDV or placebo components (including excipients).\n3. Participant has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, could interfere with the participant's ability to take part in the trial.\n4. Participant has a history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (example, Guillain-Barré syndrome).\n5. Participant has an illness, or history of any illness that, in the opinion of the investigator, might interfere with the results of the trial or pose additional risk to the participant due to involvement in this trial.\n6. Participant has a known or suspected altered immunocompetence, including:\n\n   1. Chronic administration of oral and\u002For parenteral steroids at doses considered sufficiently immunosuppressive (example, greater than or equal to \\[\\>=\\] 2 milligram per kilogram \\[mg\u002Fkg\\] body weight prednisone \\[or equivalent\\] for \\>=14 consecutive days, or \\>=20 milligram per day \\[mg\u002Fday\\] prednisone \\[or equivalent\\] administered for \\>=14 consecutive days) within 60 days prior to Day 1 (month \\[M0\\]) (note: use of corticosteroids by inhaled, intranasal, intra-articular, bursal, tendon injection, or topical routes is allowed).\n   2. Receipt of immunoglobulins and\u002For any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.\n   3. Receipt of immunostimulants within 60 days prior to Day 1 (M0).\n   4. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (M0).\n   5. Human Immunodeficiency Virus (HIV) infection or HIV-related disease.\n   6. Hepatitis B virus infection.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n7. Participant has known or suspected abnormalities of splenic or thymic function.\n8. Participant has a known bleeding diathesis, or any condition\u002Fmedication that may be associated with a prolonged bleeding time.\n9. Participant has a serious chronic or progressive disease deemed to be preclusive to trial entry, that is, not medically stable according to the judgment of the investigator.\n10. Participant has previously received a vaccination against dengue virus (investigational or licensed).\n11. Participant had a clinically significant active infection (as assessed by the investigator) or body temperature \\>38.0 degree Celsius (\\>100.4 degree Fahrenheit) within 3 days of intended TDV or placebo administration.\n12. Participant has used antipyretics and\u002For analgesic medications within 24 hours prior to vaccination. The reason for their use (prophylaxis vs treatment) must be documented. Trial entry must be delayed to allow for a full 24 hours to have passed since the last use of antipyretics and\u002For analgesic medications.\n13. Participant has a history of substance or alcohol abuse within the past 2 years.\n14. Female participants who are pregnant (that is, a positive or indeterminate pregnancy test).\n15. Female participants who are breastfeeding.\n16. Female participants of childbearing potential who are sexually active and who have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1 (M0).\n17. Female participants of childbearing potential who are sexually active and who refuse to use an acceptable contraceptive method up to 6 weeks post final vaccination on Day 90 (M3). In addition, they must also be advised not to donate ova during this period.\n18. Participant has received any of the following:\n\n    1. A licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to TDV or placebo administration on Day 1 (M0). This includes co-administration with routine vaccines.\n    2. A coronavirus vaccine within 14 days prior to TDV or placebo administration.\n    3. A vaccine authorized for emergency use within 28 days prior to TDV or placebo administration.\n19. Participant is scheduled to receive any other vaccine within 28 days after TDV or placebo administration.\n20. Participant is participating in any clinical trial with another investigational product 30 days prior to Day 1 (M0) or intending to participate in another clinical trial at any time during the conduct of this trial.\n21. Participant has taken part in any clinical trial of a dengue or other flavivirus (example, West Nile virus) candidate vaccine, except if it is known that the participant received placebo in those trials.\n22. Participant or their first-degree relatives are involved in the trial conduct.\n23. Participant identified as an employee of the investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial center.","45 Years","79 Years",{"count":54,"type":22},800,[25],"Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition.\n\nIn this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first).\n\nDuring the study, participants will visit their study clinic 5 times.",[28],[59],"Vaccination","2026-04-23",{"date":62,"type":35},"2026-04-29",{"date":64,"type":35},"2026-01-20",{"date":66,"type":22},"2027-04-14",{"name":41,"class":42},7,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":16,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":68},"100580893","a-study-in-children-and-teenagers-to-learn-if-a-tdv-dengue-vaccination-lowers-the-chance-of-hospital-stays-for-dengue-100580893","NCT06843226","A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue","The Association Between Prior Exposure to Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and Dengue Hospitalization in a Pediatric and Adolescent Population: A Nested Case-Control Post-Authorization Effectiveness Study","Inclusion Criteria:\n\nCohort:\n\nTo be eligible for inclusion in the study cohort, participants must meet the following inclusion criteria:\n\n1. The participant is a child or adolescent eligible to be vaccinated with TDV as part of a vaccination program planned in the study area.\n2. The participant's family do not intend to migrate away from the cohort hospital catchment area within 3 years of his\u002Fher enrollment into the study cohort.\n3. The participant's parent(s) or legally acceptable representative (LAR) signs and dates a written informed consent form (ICF), and any required privacy authorization where applicable, prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.\n4. The participant signs and dates an age-appropriate assent form prior to the initiation of any study procedures, after the nature of the study has been explained according to local regulatory requirements.\n5. The participant's parent(s) or LAR agrees that a baseline blood sample may be taken from the participant.\n\nCases:\n\nTo be eligible for inclusion as a case, participants must meet the following inclusion criteria:\n\n1. The participant is part of the cohort.\n2. The participant is hospitalized and clinically diagnosed with dengue.\n3. The participant has a blood sample available that was taken preferably within 5 days of fever onset and\u002For onset of symptoms compatible with dengue.\n4. The participant tested positive for dengue by RT-PCR.\n\nControls:\n\nTo be eligible for inclusion as a matched control, participants must meet the following inclusion criteria:\n\n1. The participant is part of the cohort.\n2. The participant had not been hospitalized with VCD at any point between enrollment in the cohort and the index date (that is, when his\u002Fher matched case was hospitalized with CDD).\n3. The participant is a resident in the same neighbourhood as the matched case.\n4. The participant's date of birth is in the same calendar year as the matched case.\n\nExclusion Criteria\n\nCases:\n\nTo be eligible for inclusion as a case participants must not meet any of the following criteria:\n\n1. The participant has been vaccinated with TDV, a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone (CYD-TDV), or an investigational dengue vaccine prior to cohort enrollment.\n2. Contraindications as per the locally approved label\u002Fproduct information leaflet.\n\nControls:\n\nTo be eligible for inclusion as a control participants must not meet any of the following criteria:\n\n1. The participant has been vaccinated with TDV, CYD-TDV, or an investigational dengue vaccine prior to cohort enrollment.\n2. Contraindications as per the locally approved label\u002Fproduct information leaflet.\n3. The participant could not be contacted at the time of being selected as a control.","6 Years","12 Years",{"count":79,"type":22},70000,"OBSERVATIONAL","The main aim of this study is to collect more information on the effectiveness of TDV when used in a pilot public vaccination program for children and adolescents participating in a community-based cohort in Southeast Asian countries with high dengue transmission, specifically Thailand, Indonesia, and Malaysia where TDV is already approved for use.\n\nThe study will include cohort participants (individual follow-up of 3 years) who may or may not later be vaccinated with TDV as part of a pilot public vaccination program in the study countries. The study will investigate if cohort participants who were vaccinated with TDV have less hospital stays due to dengue than cohort participants who were not vaccinated with TDV. The study will also provide further information on the effectiveness of TDV against the least common dengue virus serotypes (DENV-3 and DENV-4).",[28],[84],"Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)","2026-04-13",{"date":87,"type":35},"2026-04-16",{"date":89,"type":35},"2025-03-05",{"date":91,"type":22},"2029-12-31",{"name":41,"class":42},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":80,"phases":4,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100624455","international-registry-of-dengue-infection-in-congenital-bleeding-disorders-denguecbdr-100624455","NCT07409857","International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)","DengueCBDR","Inclusion Criteria:\n\nPatients, aged ≥ 1 day old, diagnosed with CBDs (e.g., hemophilia, von Willebrand disease, and other coagulation factor deficiency) who are diagnosed with dengue infection, based on WHO criteria as follow;\n\nClinical dengue infection:\n\nSymptoms of high sustained fever for 3-7 days with 2 of the following: headache, retroorbital pain, myalgia, arthralgia\u002Fbone pain, hemorrhagic manifestation, positive tourniquet test, leukopenia (WBC ≤5000\u002FuL)\n\nProbable dengue infection:\n\nPositive dengue IgM\n\nDefinite dengue infection:\n\nSeroconversion of dengue IgM between acute and convalescent serum OR Rising of dengue IgG (HAI) at least 4 folds between acute and convalescent serum OR Positive NS1 Ag or other dengue-specific antigen tests\n\nDengue hemorrhagic fever:\n\nDengue infection with signs of bleeding (including positive tourniquet test) with platelet count \\\u003C 100,000\u002FuL and with signs of leakage (one of the following):\n\n1. Increase Hct at least 15-20% from baseline\n2. Serum albumin \\\u003C 35 g\u002FL\n3. Presence of pleural effusion or ascites\n\nDengue shock syndrome:\n\n1. Narrow pulse pressure (\\\u003C 20 mmHg)\n2. Hypotension\n3. Signs of poor tissue perfusion\n\nSeverity of DHF:\n\n* Grade I: Positive tourniquet test\n* Grade II: Spontaneous bleeding\n* Grade III: Circulatory failure (narrow pulse pressure ≤20 mmHg, hypotension, or signs of poor tissue perfusion)\n* Grade IV: Profound shock with undetectable blood pressure\n\nExclusion Criteria:\n\n* Patients with CBDs with dengue infection who are not willing to participate in the study",{"count":101,"type":22},100,"14 Days","Dengue fever, a viral infection transmitted by Aedes mosquitoes, is a major health issue in tropical and subtropical regions. Around 20-30% of symptomatic patients developed Dengue Hemorrhagic Fever (DHF), which leads to impaired hemostasis, subsequently increasing the risk of bleeding.\n\nThe hemostatic abnormalities associated with dengue infection included vascular permeability, platelet dysfunction, and coagulation defects. Therefore, Individuals with underlying bleeding disorders are at increased risk of bleeding. Dengue infection in patients with hemophilia was reported, including six of 843 patients in the cohort with underlying hemophilia: five with hemophilia A and one with hemophilia B. Replacement therapy was more commonly used in patients with bleeding disorders and dengue than in patients with other febrile illnesses. All of them had bleeding during dengue infection. The mortality rate was high at 16%.\n\nDespite the importance of this issue, there is a lack of registries or data-collection systems to determine the bleeding complications, the requirement for replacement therapy, and the outcome of dengue infection in congenital bleeding disorders (CBDs). Therefore, this research aims to establish a registry of dengue infections among individuals with CBDs.\n\nThe study is a multicenter, retrospective study from 1 January 2015 to 31 December 2025 and a prospective cohort study involving hospitals that treat individuals with CBDs and dengue. The registry format will be provided using REDCap system.",[105,106,28,107],"Dengue Disease","Dengue Haemorrhagic Fever","Dengue Fever With Warning Signs",[109,110,111],"Dengue","Congenital bleeding disorders","Replacement","2026-02-12",{"date":114,"type":35},"2026-02-17",{"date":116,"type":35},"2025-12-01",{"date":118,"type":22},"2030-12-31",{"name":120,"class":121},"Mahidol University","OTHER",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":133,"studyType":80,"phases":4,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":122},"100593526","risk-factors-for-hospitalization-and-transfusion-criteria-in-patients-with-dengue-virus-infection-100593526","NCT07007585","Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection","Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection: A Prospective Observational Study","DENGUE-FACT","Inclusion Criteria:\n\n* Patients aged ≥5 years\n* Laboratory-confirmed dengue infection (NS1, IgM, or PCR)\n* First contact at emergency or outpatient services\n* Informed consent signed by the patient or legal guardian\n\nExclusion Criteria:\n\n* Co-infection with other arboviruses or COVID-19\n* Pre-existing hematologic or oncologic disease\n* Refusal to sign informed consent","5 Years",{"count":101,"type":22},"1 Month","This 3-year prospective observational study aims to identify clinical and laboratory risk factors associated with hospitalization in patients with confirmed dengue virus infection. It also seeks to analyze real-world transfusion practices and their outcomes. The study will be conducted in a second-level hospital in northern Mexico and will follow patients from emergency department entry to clinical resolution or hospital discharge.",[109,28,107],[109,137,138,139,140,141],"Hospitalization","Transfusion","Hemorrhagic Fever","Thrombocytopenia","Mexico","2025-09-13",{"date":144,"type":35},"2025-09-16",{"date":146,"type":35},"2025-08-01",{"date":148,"type":22},"2028-08-30",{"name":150,"class":121},"Jose Ivan Rodriguez de Molina Serrano",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100586563","phase-2-clinical-trial-evaluating-safety-and-efficacy-of-resomelagon-on-dengue-infection-resovir-2-100586563","NCT06917001","Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)","A Randomized, Double-blind, Placebo-controled, Phase 2a Trial Evaluating the Safety and Initial Efficacy of Resomelagon in Patients With Dengue Infection","RESOVIR-2","Inclusion Criteria:\n\n* Patients who are 18 to 65 years old;\n* Able to understand study procedures and give informed consent;\n* Presents with more than 36 and less than 84h since symptoms onset;\n* Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.\n\nExclusion Criteria:\n\n* Has any comorbidity which is perceived as significant by the investigator;\n* Significant laboratory abnormalities discovered at triage: Hemoglobin \\\u003C10g\u002FdL; Platelet count \\\u003C 50.000\u002FmicroL; alanine transaminase \\> 3x upper limit of normal; Total bilirubin \\>1,5 x upper limit of normal; glomerular filtration rate \\\u003C 60mls\u002Fmin\u002F1,73m2;\n* Contraindications or known hypersensitivity to Resomelagon;\n* Presents as dengue with warning signs or severe dengue at inclusion;\n* Currently participating in another drug clinical trial;\n* Clinical evidence of another infection that might explain current symptoms;\n* Pregnant women or women actively trying to achieve pregnancy.","18 Years","65 Years",{"count":162,"type":22},120,[164],"PHASE2","The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are:\n\nIs Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.",[28],[168,169,170,109,157],"Resomelagon","Resolution of inflammation","Melanocortin","NOT_YET_RECRUITING","2025-08-27",{"date":174,"type":35},"2025-08-28",{"date":176,"type":22},"2026-02",{"date":178,"type":22},"2027-12",{"name":180,"class":121},"Federal University of Minas Gerais",2,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":159,"enrollmentInfo":189,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100601619","prospective-clinical-registry-for-evaluation-of-exanthematous-infections-and-coinfections-100601619","NCT07112846","Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","CRIUS","Inclusion Criteria:\n\nIndividuals from newborns (zero years old) to 18 years of age, of both sexes.\n\nSuspected individuals with the following criteria:\n\nMeasles: Presenting fever and rash associated with cough and\u002For runny nose and\u002For conjunctivitis, regardless of age or vaccination status;\n\nRubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;\n\nDengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and\u002For lymph node enlargement;\n\nIndividuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases.\"\n\nExclusion Criteria:\n\n\\-",{"count":190,"type":22},830,"Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.",[193,28,194,195,196],"Exanthema","Chikungunya","Measles","Rubella",[198,199,194,200,201,202],"exanthema","dengue fever","measles","rubella","epidemiology",{"date":204,"type":35},"2025-08-08",{"date":206,"type":22},"2025-09-01",{"date":208,"type":22},"2026-06-30",{"name":210,"class":121},"Hospital Israelita Albert Einstein",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":181},"100408358","phase-2-zanamivir-treatment-of-vascular-permeability-in-dengue-zap-dengue-100408358","NCT04597437","Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)","Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial","ZAP-DENGUE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged \\>7 years\n4. Willingness to receive intravenous medication and be willing to adhere to the medication regimen\n5. Have a diagnosis of dengue by dengue NS1 rapid test\n6. Have had a self-informed fever \\>38 degrees C in the last 3 days.\n7. Have dengue with warning signs as per the 2009 WHO criteria including one of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm, augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe plasma leakage leading to dengue shock and\u002For fluid accumulation with respiratory distress; severe hemorrhage; severe organ impairment (hepatic damage, renal impairment, cardiomyopathy, encephalopathy or encephalitis).\n8. Enrollment in EPS (Entidadas Promotoras de Salud) or Sistema General de Seguridad Social en Salud (SGSSS)- Colombian Public Health Insurance.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Children in Care of the state\n3. Patients who are unlikely to survive 48 hours\n4. Unstable cardiac disease or arrhythmia at baseline\n5. History of significant cardiac disease\n6. Treatment with another investigational drug or other intervention within 1 month.\n7. Encephalitis or unable to consent","7 Years",{"count":221,"type":22},74,[164],"ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.",[28],"2025-07-23",{"date":227,"type":35},"2025-07-28",{"date":229,"type":35},"2024-03-15",{"date":231,"type":22},"2026-09-30",{"name":233,"class":121},"George Washington University"]